Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis
Public ClinicalTrials.gov record NCT02026401. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Pharmacodynamic Activity of NGM282 in Combination With Ursodeoxycholic Acid (UDCA) Administered for 28 Days in Patients With Primary Biliary Cirrhosis
Study identification
- NCT ID
- NCT02026401
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- NGM Biopharmaceuticals, Inc
- Industry
- Enrollment
- 45 participants
Conditions and interventions
Conditions
Interventions
- NGM282 Biological
- Placebo Biological
Biological
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2014
- Primary completion
- Nov 30, 2014
- Completion
- Nov 30, 2014
- Last update posted
- Mar 27, 2017
2014
United States locations
- U.S. sites
- 7
- U.S. states
- 6
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| NGM Clinical Study Site 103 | Phoenix | Arizona | — | — |
| NGM Clinical Study Site 108 | Coronado | California | — | — |
| NGM Clinical Study Site 101 | Detroit | Michigan | — | — |
| NGM Clinical Study Site 105 | Durham | North Carolina | — | — |
| NGM Clinical Study Site 102 | Dallas | Texas | — | — |
| NGM Clinical Study Site 113 | San Antonio | Texas | — | — |
| NGM Clinical Study Site 104 | Richmond | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02026401, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 27, 2017 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02026401 live on ClinicalTrials.gov.